All Technologies

Anti-HIV formulation. An active principle for the preparation of OTC formulations, available as emergency protection against HIV-I infection during heterosexual invasive contact and/or vaginal contraceptive. A method for simultaneous prevention of HIV infection and unwanted pregnancy in a subject, comprising administering a therapeutically effective amount of the compound Ac-B, derivatives, analogues and pharmaceutically acceptable salts

Ac-B has an anti-HIV property and capable to prevent HIV infection at a dose level of greater than or equal to 1.0 microgram per ml in vitro, which is perhaps well within tolerable limits ( Hemolytic index: 7 microgram per ml). MEC of Ac-B is 125micro g/ml for spermicidal activity on human sperm which is significantly lower than that of closest prior arts (MEC for N-9:200-500 microgram/ml through vaginal route. Significant spermicidal as well as virucidal activities with apparently no possible mutagenic effects and adverse effects on vaginal ecology. Ac-B is non-mutagenic as tested in Ames Test. Ac-B does not interfere with the growth of Lactobacillus acidophilus in laboratory culture, at least up to a concentration of 500 mg/ml. Thus it application does not lead to an increased risk of opportunistic infections. Its molecular size is about three fold higher than N-9, which makes it likely to be absorbed weekly through vaginal route.